IGNITE: Study of Tirabrutinib vs Rituximab/Temozolomide for Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL)

NCT07104032 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

132

Enrollment

INDUSTRY

Sponsor class

Conditions

Relapsed/Refractory Primary Central Nervous System Lymphoma

Interventions

DRUG: Tirabrutinib
DRUG: Rituximab
DRUG: Temozolomide

Sponsor

Ono Pharmaceutical Co., Ltd.

Collaborators

[object Object]